Clinical effects of gemifloxacin on the delay of tuberculosis treatment

Journal of Korean Medical Science

Volumn 28, Issue 3, 2013, Pages 378-382

  Kim, Seo Yun ^a   Yim, Jae Joon ^a   Park, Jong Sun ^a,c   Park, Sung Soo ^a,b   Heo, Eun Young ^a,b   Lee, Chang Hoon ^a   Chung, Hee Soon ^a,b   Kim, Deog Kyeom ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Fluoroquinolones; Pneumonia; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT; GEMIFLOXACIN; NAPHTHYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MIDDLE AGED; PNEUMONIA; RADIOGRAPHY; TUBERCULOSIS;

FLUOROQUINOLONES; PNEUMONIA; TUBERCULOSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; FLUOROQUINOLONES; HUMANS; MIDDLE AGED; NAPHTHYRIDINES; PNEUMONIA; TUBERCULOSIS;

EID: 84875800303     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.3.378     Document Type: Article

References (21)

1. WHO global tuberculosis control report 2010: summary. Cent Eur J Public Health 2010; 18: 237.
2. Pablos-Méndez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223-8.
3. Sherman LF, Fujiwara PI, Cook SV, Bazerman LB, Frieden TR. Patient and health care system delays in the diagnosis and treatment of tuberculosis. Int J Tuberc Lung Dis 1999; 3: 1088-95.
4. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, Luh KT. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-8.
5. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72.
6. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
7. Lew WJ. The up-to-date of anti-tuberculosis treatment. Tuberc Respir Dis 2006; 60: 270-6.
8. Yoon YS, Lee HJ, Yoon HI, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005; 9: 1215-9.
9. Jeon CY, Calver AD, Victor TC, Warren RM, Shin SS, Murray MB. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int J Tuberc Lung Dis 2011; 15: 77-83.
10. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607-12.
11. Lee HS, Kang YA, Oh JY, Lee JH, Yoo CG, Lee CT, Kim YW, Han SK, Shim YS, Yim JJ. A case of pulmonary tuberculosis with delayed diagnosis due to the temporary clinical improvement after use of levofloxacin and amikacin under the impression of community acquired pneumonia. Tuberc Respir Dis 2003; 55: 395-401.
12. Ruiz-Serrano MJ, Alcalá L, Martínez L, Díaz M, Marín M, González-Abad MJ, Bouza E. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567-8.
13. Tan CK, Lai CC, Liao CH, Chou CH, Hsu HL, Huang YT, Hsueh PR. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 428-9.
14. Lai CC, Tan CK, Huang YT, Chou CH, Hung CC, Yang PC, Luh KT, Hsueh PR. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. Clin Infect Dis 2008; 47: e57-63.
15. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99: 1025-6.
16. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 1998; 26: 874-7.
17. Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1995; 49: 67-75.
18. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67: 2077-99.
19. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004; 48: 1281-8.
20. Cardoso MR, Nascimento-Carvalho CM, Ferrero F, Berezin EN, Ruvinsky R, Camargos PA, Sant'anna CC, Brandileone MC, de Fátima P, March M, et al. Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia. Arch Dis Child 2008; 93: 221-5.
21. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992; 146: 920-3.